Researchers at the University of Utah asked, on behalf of the entire human race, “Why us?”
They posed this question in regards to our much higher incidence of cancer compared to large mammals such as the elephant. Based on their data, the lifetime risk of cancer in an elephant is less than five percent, compared to approximately 20 percent for humans. This finding is counterintuitive because:
The Elephant Experiment:
Their results were published this month in the Journal of the American Medical Association (JAMA). To conduct the experiment:
The Results:
The findings:
What Do These Results Mean?
Presumably, elephants’ lower cancer rate is a result of natural selection. Elephants reproduce throughout their life span, even into their 60s and 70s. According to anthropologists, elderly males have an elevated status, which increases their reproductive opportunities at an older age.
Perhaps this reproductive norm necessitated a more efficient means of cancer suppression. The authors note that both African and Asian elephants have 20 copies of TP53, suggesting that this cancer suppression ability existed prior to their divergence more than 6 million years ago. Perhaps humans will have similar luck, if our species exists several million years from now.
Improving Cancer Care
So, can we use this knowledge to improve cancer care? The promise of using viral vectors (tools to deliver genetic material into cells) to insert functional TP53 genes into the cancer cells is not a new idea. However, it is not an easy task.
There are ongoing studies in this field in lung cancer and other cancers. Perhaps the findings of these scientists will give us new insight into the potential of this treatment. From my perspective, the human (and elephant) interest aspect of this piece stands alone. Kudos to the scientific team for exploring the 35-year-old question dubbed “Peto’s paradox”: why large mammals with more cells don’t have a higher incidence of cancer.
Inova Loudoun Hospital scores an ‘A’ for 25 consecutive grading periods Fairfax, VA, May 1,…
According to the U.S. Centers for Disease Control and Prevention, nearly 50% of adults in…
Heather Perez Saiz, MA, LCSW, CCTSW, is the Independent Living Donor Advocate at Inova Fairfax…
Palak Shah, MD, MS Fairfax, VA — A research team at Inova Schar Heart and…
Jason Bonomo, MD, PhD, is a cardiologist at Inova Schar Heart and Vascular. Dr. Bonomo…
Update as of April 24, 2024: Inova’s structural heart team has now completed the first…